Annual Drug Patent Expirations for POMALYST
Pomalyst is a drug marketed by Celgene and is included in one NDA. It is available from one supplier. There are eleven patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for POMALYST.
This drug has three hundred and thirty-nine patent family members in forty-seven countries.
The generic ingredient in POMALYST is pomalidomide. One supplier is listed for this compound. Additional details are available on the pomalidomide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
